A multicenter retrospective study to evaluate the efficacy and safety of platinum-based chemotherapy in combination with immunotherapy for extensive-stage small cell lung cancer in the real-world setting

A multicenter retrospective study to evaluate the efficacy and safety of platinum-based chemotherapy in combination with immunotherapy for extensive-stage small cell lung cancer in the real-world setting - Efficacy and safety of combination-immunotherapy for ES-SCLC

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000053134

Enrollment

350

Registered

2024-01-20

Start date

2024-01-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

extensive-stage small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Extensive-stage small cell lung cancer Patients who received first-line platinum-based chemotherapy in combination with immunotherapy and Patients who received first-line platinum-based chemotherapy

Exclusion criteria

Exclusion criteria: Patients who are judged by the attending doctor as inappropriate to participate in this clinical research

Design outcomes

Primary

Measure	Time frame
Overall survival (Patients with platinum-based chemotherapy in combination with immunotherapy and Patients with platinum-based chemotherap)	—

Secondary

Measure	Time frame
Progression free survival Objective response rate 1 year-OS, 2 year-OS Safety(severe toxicity)	—

Countries

Japan

Contacts

Public ContactKei Sonehara

Shinshu University School of Medicine First Department of Internal Medicine

soneponpon@shinshu-u.ac.jp0263-37-2631

Outcome results